EMA Biosimilars Pathway Explained: Ultimate Guide to EU Approvals, Compliance, and Regulatory Lessons Mastering the EMA Biosimilars Pathway: Compliance-Ready Guide for Regulatory Affairs Professionals Introduction to EMA Biosimilars Pathway and Its Importance EMA’s biosimilars pathway is the regulatory framework established by the European Medicines Agency (EMA) for the approval of biosimilar medicines in the European Union. A biosimilar is a biological medicine highly similar to an already approved reference product, with no clinically meaningful differences in terms of quality, safety, and efficacy. The EMA was the first regulator globally to establish a biosimilars pathway in 2005, setting the global standard….